A Study to Investigate the Safety of DSP-3077 After a Unilateral Eye Injection in Male and Female Participants 18 Years of Age or Older With Retinitis Pigmentosa

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

Retinitis Pigmentosa

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Massachusetts Eye and Ear, Boston, Massachusetts, United States
Contact: Study coordinator (Albert Cheng) · acheng18@meei.harvard.edu · 617-573-6060
University of Minnesota, Minneapolis, Minnesota, United States
Contact: Study coordinator (Jacob Stauffer) · jstauffe@umn.edu · 612-625-4108

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

A Phase II Study of Intravitreal KIO-301 in Patients With Late-stage Retinitis Pigmentosa

Retinitis Pigmentosa

Abroad (travel likely)RecruitingPHASE2

Sydney, Australia · Woolloongabba, Australia

Safety of a Single, Intravitreal Injection of 6.0M jCell (Famzeretcel) in Retinitis Pigmentosa (RP)

Retinitis Pigmentosa

Abroad (travel likely)RecruitingPHASE2

Phoenix, United States · Bakersfield, United States

BS01 in Patients With Retinitis Pigmentosa

Retinitis Pigmentosa

Abroad (travel likely)RecruitingPHASE1, PHASE2

Teaneck, United States

Safety and Efficacy of Stem Cell Small Extracellular Vesicles in Patients With Retinitis Pigmentosa

Retinitis Pigmentosa

Abroad (travel likely)RecruitingPHASE1, PHASE2

Bangkok Noi, Thailand